- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07663305
Evaluation of a Mobile Menopause Application (EMMA)
This study examines whether a digital app can help women manage symptoms of menopause. A total of 426 women with medically confirmed menopausal symptoms are randomly assigned to either use the app in addition to their usual medical care for 24 weeks, or to continue with usual care alone. The app provides evidence-based content and exercises for multimodal menopause management. Participants are followed up over 24 weeks, with the primary outcome assessed at 12 weeks. The main goal is to evaluate whether the app improves menopause-specific quality of life.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Hanover, Germany
- Recruiting
- Medicoles
-
Principal Investigator:
- Elisabeth Siegmund-Schultze, Dr. med.
-
Contact:
- Elisabeth Siegmund-Schultze, Dr. med.
- Email: studienleitung@wechseljahr-studie.de
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Legal capacity
- Ability to provide informed consent
- Residency in Germany
- Female gender
- Age ≥18 years
- Medically confirmed menopausal or other perimenopausal disorder (N95.1)
- Ownership of a smartphone and ability to use it
- Internet access for app usage and questionnaire completion
- Email address for registration
- Willingness to complete questionnaires online
- Motivation for regular app usage
- Sufficient proficiency in the German language
- MRS II ≥ 9
- Absence of exclusion criteria
Exclusion Criteria:
- Pregnancy or breastfeeding during the study period
- Current hormonal replacement therapy (HRT), initiation of HRT within eight weeks prior to study start and/or planned start of HRT during the study period
- Changes in treatment with psychotropic medication within eight weeks prior to study start and/or planned during the study period
- Start of psychotherapy within eight weeks prior to study start and/or planned during the study period
- Start of a rehabilitation program within eight weeks prior to study start and/or planned during the study period
- Surgery performed within eight weeks prior to study start and/or planned during the study period
- Previous or current access to the Endo-App or other comparable digital health applications, or current active prescription
- Current participation in other clinical studies
- Failure to meet the inclusion criteria
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
No Intervention: Control Group
The control group has access to care-as-usual only. |
|
|
Experimental: Intervention Group
The intervention group has access to the menopause app and its functions in addition to care-as-usual. |
The menopause app facilitates the implementation of multimodal self-management strategies in the daily routines of individuals with a menopausal disorder, through tools such as a symptom diary and guided interactive exercises. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Menopause-specific quality of life
Time Frame: Changes between time point T0 (baseline) and T3 (12 weeks after baseline)
|
Assessed with the Menopause-specific Quality of Life Questionnaire (MENQOL) |
Changes between time point T0 (baseline) and T3 (12 weeks after baseline)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Menopause-specific symptom severity
Time Frame: Changes between time point T0 (baseline) and T3 (12 weeks after baseline)
|
Assessed with the Menopause Rating Scale (MRS II) |
Changes between time point T0 (baseline) and T3 (12 weeks after baseline)
|
|
Daily interference due to hot flashes
Time Frame: Changes between time point T0 (baseline) and T3 (12 weeks after baseline)
|
Assessed with the Hot Flash Related Daily Interference Scale (HFRDIS) |
Changes between time point T0 (baseline) and T3 (12 weeks after baseline)
|
|
Menopause-specific impairment in daily activities
Time Frame: Changes between time point T0 (baseline) and T3 (12 weeks after baseline)
|
Assessed with the Activity Impairment domain of the Work Productivity and Activity Impairment-Menopause questionnaire (WPAI-Menopause) |
Changes between time point T0 (baseline) and T3 (12 weeks after baseline)
|
|
Patient activation
Time Frame: Changes between time point T0 (baseline) and T3 (12 weeks after baseline)
|
Assessed with the Patient Activation Measure 13 (PAM-13) |
Changes between time point T0 (baseline) and T3 (12 weeks after baseline)
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Menopause-specific quality of life
Time Frame: Changes between time point T0 (baseline) and T4 (24 weeks after baseline)
|
Assessed with the Menopause-specific Quality of Life Questionnaire (MENQOL) |
Changes between time point T0 (baseline) and T4 (24 weeks after baseline)
|
|
Menopause-related absenteeism
Time Frame: Changes between time point T0 (baseline) and T3 (12 weeks after baseline)
|
Assessed with the absenteeism domain score of the Work Productivity and Activity Impairment-Menopause questionnaire (WPAI-Menopause). |
Changes between time point T0 (baseline) and T3 (12 weeks after baseline)
|
|
Menopause-related presenteeism
Time Frame: Changes between time point T0 (baseline) and T3 (12 weeks after baseline)
|
Assessed with the presenteeism domain score of the Work Productivity and Activity Impairment-Menopause questionnaire (WPAI-Menopause). |
Changes between time point T0 (baseline) and T3 (12 weeks after baseline)
|
|
Menopause-related work productivity loss
Time Frame: Changes between time point T0 (baseline) and T3 (12 weeks after baseline)
|
Assessed with the work productivity loss domain score of the Work Productivity and Activity Impairment-Menopause questionnaire (WPAI-Menopause). |
Changes between time point T0 (baseline) and T3 (12 weeks after baseline)
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- RCT_EMMA
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.